How to Read a Longevity Study Before You Act on It

Six checks that separate a usable finding from a press release.

Start with the species. A great deal of longevity content rests on mouse, worm, or yeast work where the intervention has never been tested in humans at a comparable dose.

Then the endpoint. Surrogate markers — a biomarker panel, an epigenetic clock reading, a cell-culture measure — are not the same as morbidity or mortality, and interventions that move surrogates frequently fail on hard outcomes.

Then the comparison, the sample size, the duration, and the funding. A twelve-week trial in twenty participants against a no-treatment control is a hypothesis, not a protocol. Ask what the absolute risk change was, not the relative one: a 50% reduction of a 0.2% risk is 0.1%.

Editorial note: this article summarises published research for general information. It is not medical advice. Discuss any intervention with a qualified clinician.